BI-836858
Based on 1 Customer Validation
BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.81%
- Masse moléculaire:143.86 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
BI-836858 (10 μg/mL; 30 min) mediates specific ADCC activity against primary AML blasts[1].
BI-836858 (2 μg/mL; 4 h) mediates NK cell-dependent ADCC activity against CD33-positive HL60 cells[2].
BI-836858 (2 μg/mL; 48 h) blocks the CD33-mediated inhibitory signaling pathway in MDS bone marrow cells and reduces the expression of IL-10 and TGFβ[2].
BI-836858 (2 μg/mL) specifically blocks CD33 (S100A9)-mediated ROS production in U937 cells, healthy PBMCs, and primary MDS BM HSPCs[2].
BI-836858 (2 μg/mL; 14 days) restores the hematopoietic colony-forming capacity in ex vivo cultures of primary MDS bone marrow specimens[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized huCD33-his can bind BI-836858. The EC50 for this effect is 9.98 ng/mL.
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 143.86 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Gopalakrishnan B, et al. Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget. 2018;9(11):9706-9713. Published 2018 Jan 3. [Content Brief]
[2]. Eksioglu EA, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172-2180. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BI-836858 Related Classifications
HY-P991517 Related Classifications
Powered by Bioz